Quinolones Flashcards
Intro
A. Aminoquinolines: e.g. chloroquine, primaquine (antimalarial drugs – see under antiprotozoals)
B. Hydroxy-(Halogenated-)quinolines: e.g. chlorquinaldole
C. Isoquinoline derivatives (e.g. papaverine, praziquantel)
D. Quinolone carboxilic acids Quinolone carboxylic acid derivatives are synthetic antimicrobial agents.
STRUCTURE EFFECT RELATIONSHIP
Antibacterial effect:
3. position: carboxyl attaching to
4. position: ketone site of action
Broader spectrum:
6. position: fluor
1. position: cyclopropyl, ethyl, fluorophenyl
5. position: NH2, CH3, fluor
7. position: piperazine, diazabicyclonil
8. position: fluor, methoxi, CIANO (8-ciano-quinolones)
- generation quinolones (4-quinolones)
Nalidixic acid, Oxolinic acid, Cinoxacin
Narrow spectrum; Gram-negatives, enteric bacteria =>moderate
SC, IM
Obsolete, for non-complicated UTI (rapid elimination via urine)
- generation fluoroquinolones
Flumequine, Norfloxacin Sus, Av=> GI, resp, UTI \+ fish Aeromonas Wider spectrum; Gram-negatives, enteric bacteria=> good PO (not with food), SC, IM
- generation fluoroquinolones
Pefloxacin, Ciprofloxacin,-Hu Ofloxacin, Danofloxacin, -Lactating cows, Sus Difloxacin, - dog, Bo (not PO) + Eq Enrofloxacin, -Lactating cows, Sus, Poultry, SA+ Eq Ibafloxacin, - SA, only PO Marbofloxacin, - LA (not PO), SA + Eq Orbifloxacin, -SA (only PO) Sarafloxacin
PO (not with food), SC, IM
Wide spectrum, mainly fastidious G(-)
Gram-negatives => pronounced
P. aeruginosa => pronounced (mainly ciprofloxacin)
Gram-positives => moderate (Staph + Mycobacterium)
Intracellular pathogens => good
+ Mycoplasma, Chlamydia, Staph
Primarily resistant: obligate anaerobic bacteria, streptococci, enterococci
- generation fluoroquinolones (mainly Hu)
Balofloxacin,
Levofloxacin,
Sparfloxacin,
Temafloxacin,
PO, SC, IM Gram-positives => good-pronounced Gram-negatives => good-pronounced P. aeruginosa => good-pronounced Intracellular pathogens => pronounced Same as Gen 2.2 + STREP
- generation fluoroquinolones (mainly Hu)
Gatifloxacin, Gemifloxacin, Moxifloxacin, Trovafloxacin, Pradofloxacin- SA (only PO)
Gram-positives => pronounced Gram-negatives => good-pronounced P. aeruginosa => good-pronounced Anaerobes => good-pronounced Intracellular pathogens => pronounced
MODE OF ACTION
BACTERICIDAL concentration-dependent! + Post-Antibacterial Effect /PAE/ 2-5 hrs.
RESISTANCE
Significant! Antimicrobial Advice Ad Hoc Expert Group (AMEG) B category
Chromosomal mutation. Its developing is relatively fast, when drugs are used „heavily”,
• Changes in gyrase A gene (gyr-A) resistance against 1st gen.
• Changes in both gyrase A and B gene (gyr-A, gyr-B) ) full resistance.
Frequent in zoonotic E. coli, Salmonella and Campylobacter strains.
- Chromosomal resistance stays for a long time
Other mechanisms:
• Membrane proteins (inhibited penetration)
• Increased bacterial efflux (membrane-proteins actively pump the drug out from bacteria) Cross resistance is complete within the groups (generations)! limitations?
Plasmid mediated resistance mechanism (qnr-gene) - recent
• reduced susceptibility (Enterobacteriaceae) – significance
PHARMACOKINETICS 1.
Absorption
-(except 1st generation) Excellent absorption PO (food – delays time to peak), good bioavailability in monogastric species (very poor in adult cattle).
-Divalent or trivalent cations (e.g. Ca, Fe, Mg, Zn or Al) may reduce the absorption.
- SC., IM. good absorption
• Distribution - (except 1st generation)
- Excellent, very high Vd. High concentrations in bile, urine, prostate. Quinolones appear in milk.
- Good penetration through special barriers (CSF, ocular fluids)!
- Concentrated within phagocytic cells (reduction of survival of intracellular pathogens).
• Metabolism
- Partially metabolised (1st generation more complete).
- Metabolites may also be active. e.g. Enrofloxacin → Ciprofloxacin (deethylation of the ethyl group on the piperazine ring)
• Elimination
- Mainly via kidneys (tubular secretion) as active drug, partially with bile (e.g. inactive glucuronide ester).
- Enterohepatic recirculation, reduction of metabolite by gut-bacteria»_space;> prolonged action
- In active form – urinary tract infections: E. coli, Klebsiella spp., Proteus spp., Pseudomonas spp. Staphylococcus spp.
Safety
-majority safe, 1st gen more toxic
• Long lasting administration and/or too large doses may increase the possibility of unwanted side-effects.
• During the administration of fluoroquinolones the risk-benefit ratio has to be considered
• Recent FQs are neither mutagenic nor teratogenic.
• Can decrease CYP3A- and CYP1A-mediated biotransformation by competitive inhibition
SIDE EFFECTS
Inhibition of load-bearing cartilage development (young animals & horses! )
- Retinopathy (Fe!) leading to blindness (higher doses, enrofloxacin)
- CNS-signs (Epilepsy! Quinolones may pre-dispose the seizure activity)
- Dysbacteriosis (horses)
- Others (observed mainly in human beings)
FLUOROQUINOLONES are synergistic with
- betalactams
- aminoglycosides
- Vancomycin
e.g. Staphylococcus aureus (Ciprofloxacin + Azlocillin; Levofloxacin + Oxacillin)
Pseudomonas aeruginosa (Ciprofloxacin + Imipenem or Azlocillin or Amikacin)
Enterococci (Ciprofloxacin + Imipenem or Ampicillin or Vancomycin)
Expanded antibacterial spectrum with Metronidazole.
ANTAGONISTIC INTERACTIONS (Ciprofloxacin with):
- Chloramphenicol - Rifampin
INTERACTIONS 2.
- May increase anticoagulant effects of Warfarin
- May increase Caffeine & Theophylline levels (liver)
- May increase Cyclosporine levels
- May prolong QTc if used concomitantly with antiarrhythmics (e.g., class IA and III agents) or with Cisapride
- May increase risk of CNS stimulation and convulsions if used with NSAIDs
- May lead to hypoglycaemia and/or hyperglycemias if used concomitantly with oral hypoglycemics or insulin
- Gatifloxacin; increased serum Digoxin levels
- Probenicid may increase Ciprofloxacin levels (kidney)